drugset / Trial / NCT00669409
A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety and tolerability of single IV doses of PF-04383119 in Japanese patients with moderate to severe pain from OA of the knee (Part I). To evaluate the preliminary analgesic efficacy of PF-04383119 in Japanese patients with moderate to severe pain from OA of the knee in comparison with placebo (Part I and Part II).
Timeline
- Start
- 2008-06-06
- Primary completion
- 2009-12-25
- Completion
- 2009-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tanezumab | Monoclonal antibody | 10 ug/kg | Intravenous |
| Comparator | Tanezumab | Monoclonal antibody | 25 ug/kg | Intravenous |
| Comparator | Tanezumab | Monoclonal antibody | 50 ug/kg | Intravenous |
| Comparator | Tanezumab | Monoclonal antibody | 100 ug/kg | Intravenous |
| Comparator | Tanezumab | Monoclonal antibody | 200 ug/kg | Intravenous |